---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-26-000002"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:21:13.194842+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie cuts Q4 2025 adjusted EPS guidance by $0.71 on $1.265B IPR&D charge

## Summary
- Q4 2025 adjusted EPS guidance revised to $2.61-$2.65 from prior $3.32-$3.36.
- Full-year 2025 adjusted EPS guidance lowered to $9.90-$9.94 from $10.61-$10.65.
- Pre-tax acquired IPR&D and milestones expense of $1,265M (unfavorable $0.71 to GAAP and adjusted EPS).
- Q4 2025 results not finalized; expense relates to collaborations and licensing deals.
- AbbVie does not forecast IPR&D/milestones expense due to uncertainty.

## SEC filing metadata
- accession: 0001551152-26-000002
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000002/0001551152-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000002/abbv-20260107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-26-000002
- JSON: https://secwatch.observer/filing/0001551152-26-000002.json
- Plain text: https://secwatch.observer/filing/0001551152-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.